// App-Quantinova.ai

4759 : Identification of ALK, ROS1, FGFR2 and NRG1 fusions and validation with targeted inhibitors in lung and ovarian PDX models

Researchers

Presenter

  • Xuzhen Tang

Principal Investigators

  • Hua Dong

  • Yibo Gao

  • Zhixiang Zhang

  • Xiangnan Qiang

  • Baoyuan Zhang

  • Yuxin Qin

  • Shuqun Yang

  • Yunbiao Yan

  • Qingyang Gu

  • Norman Zhang

  • Jie He

  • Qunsheng Ji

Medical Centers

  • WuXi AppTec, Shanghai, China

  • Chinese Academy of Medical Sciences, Beijing, China

Locations

  • China

Companies

  • WuXi AppTec Co., Ltd

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Gynaecological cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • Ph chromosome

  • Proto-oncogene tyrosine-protein kinase ROS

  • Fibroblast Growth Factor Receptor 2

Drug/Treatment

  • Crizotinib

  • Imatinib

  • IkT001

  • AP-26113

  • Ceritinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved